COVID-19 in patients with hematologic malignancy
P Langerbeins, M Hallek - Blood, The Journal of the American …, 2022 - ashpublications.org
The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …
COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current …
To date, four vaccines have been authorised for emergency use and under conditional
approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 …
approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 …
[HTML][HTML] Seroconversion rates following COVID-19 vaccination among patients with cancer
As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically
needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we …
needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we …
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
EM Bange, NA Han, P Wileyto, JY Kim, S Gouma… - Nature medicine, 2021 - nature.com
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …
Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer
Importance As the COVID-19 pandemic continues, understanding the clinical outcomes of
patients with cancer and COVID-19 has become critically important. Objective To compare …
patients with cancer and COVID-19 has become critically important. Objective To compare …
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …
[HTML][HTML] Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity,
complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are …
complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are …
Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative
Q Song, B Bates, YR Shao, FC Hsu, F Liu… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide real-world evidence on risks and outcomes of breakthrough COVID-
19 infections in vaccinated patients with cancer using the largest national cohort of COVID …
19 infections in vaccinated patients with cancer using the largest national cohort of COVID …
Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a …
Importance SARS-CoV-2 infection has been associated with more severe disease and
death in patients with cancer. However, the implications of certain tumor types, treatments …
death in patients with cancer. However, the implications of certain tumor types, treatments …
Outcomes of COVID-19 in patients with cancer: report from the National COVID Cohort Collaborative (N3C)
PURPOSE Variation in risk of adverse clinical outcomes in patients with cancer and COVID-
19 has been reported from relatively small cohorts. The NCATS'National COVID Cohort …
19 has been reported from relatively small cohorts. The NCATS'National COVID Cohort …